[1] OttJJ, Stevens GA,Groeger H,et al. Global epidemiology of hepatitis B virus infection:new estimates of age specific HBsAg seroprevalence and endemicity. Vaccine,2012,30:2212-2222.
[2] Lozano R,Naghavi M,Foreman K,et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010:a systematic analysis for the Global Burden of Disease Study 2010. Lancet,2012,380:2095-2099.
[3] Chan HL,Ompson A,Martinot-Peignoux M,et al. Hepatitis B surface antigen quantication:why and how to use it in 2011 a core group report. J Hepatol,2011,55:1121-1131.
[4] Rijckborst V,Hansen BE,Ferenci P,et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol,2012,56:1006-1011.
[5] Sonneveld MJ,Zoutendijk R,Janssen HL. Hepatitis B surface antigen monitoring and management of chronic hepatitis B. J Viral Hepat,2011,18:449-457.
[6] Liaw YF. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B:a review. Hepatology,2011,53:2121-2129.
[7] Chan HL,Wong VW,Tse AM,et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol, 2007,5:1462-1468.
[8] Lampertico P,Vigano M,Colombo M. Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon. Liver Int,2013,33（Suppl 1）:157-163.
[9] Peng CY,Lai HC,Li YF,et al. Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Aliment Pharmacol Ther,2012,35:458-468. |
